Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I / II trial of doxorubicin + durvalumab in advanced soft tissue sarcoma
KCT0003577Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of doxorubicin and durvalumab in soft tissue sarcoma (STS), sponsored by AstraZeneca. Started Sep 2019; status: completed.
02
Drugs
doxorubicindurvalumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on KCT0003577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003577.